{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:28:06Z","timestamp":1774542486646,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["11807"],"award-info":[{"award-number":["11807"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-025-01275-x","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:35:26Z","timestamp":1752572126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of androgen blockade on [68Ga]Ga-PSMA-11 and [18F]FDG PET uptake in patients with recurrent or metastatic salivary duct carcinoma: a prospective imaging study"],"prefix":"10.1186","volume":"15","author":[{"given":"Niels J.","family":"van Ruitenbeek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike J. M.","family":"Uijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal M. L.","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maartje C.","family":"van Rijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffie M. B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastiaan M.","family":"Priv\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald W.","family":"Verhaegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana C. H.","family":"van Engen-van Grunsven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Gotthardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Nagarajah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5130-5451","authenticated-orcid":false,"given":"Carla M. L.","family":"van Herpen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"6","key":"1275_CR1","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1245\/s10434-015-5082-2","volume":"23","author":"K Otsuka","year":"2016","unstructured":"Otsuka K, Imanishi Y, Tada Y, Kawakita D, Kano S, Tsukahara K, et al. Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients. Ann Surg Oncol. 2016;23(6):2038\u201345.","journal-title":"Ann Surg Oncol"},{"key":"1275_CR2","doi-asserted-by":"crossref","unstructured":"Sk\u00e1lov\u00e1 A, Hyrcza MD, Leivo I. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Salivary Glands. Head Neck Pathol. 2022;16(1):40\u201353.","DOI":"10.1007\/s12105-022-01420-1"},{"issue":"4","key":"1275_CR3","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/ijc.31353","volume":"143","author":"E Boon","year":"2018","unstructured":"Boon E, Bel M, van Boxtel W, van der Graaf WTA, van Es RJJ, Eerenstein SEJ, et al. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands. Int J Cancer. 2018;143(4):758\u201366.","journal-title":"Int J Cancer"},{"key":"1275_CR4","doi-asserted-by":"crossref","unstructured":"Boon E, van Boxtel W, Buter J, Baatenburg de Jong RJ, van Es RJJ, Bel M, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. Head Neck. 2018;40(3):605\u201313.","DOI":"10.1002\/hed.25035"},{"key":"1275_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.oraloncology.2017.09.008","volume":"74","author":"NC Schmitt","year":"2017","unstructured":"Schmitt NC, Kang H, Sharma A. Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy. Oral Oncol. 2017;74:40\u20138.","journal-title":"Oral Oncol"},{"issue":"35","key":"1275_CR6","doi-asserted-by":"publisher","first-page":"59023","DOI":"10.18632\/oncotarget.19812","volume":"8","author":"S Takase","year":"2017","unstructured":"Takase S, Kano S, Tada Y, Kawakita D, Shimura T, Hirai H, et al. Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget. 2017;8(35):59023\u201335.","journal-title":"Oncotarget"},{"issue":"4","key":"1275_CR7","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdx771","volume":"29","author":"C Fushimi","year":"2018","unstructured":"Fushimi C, Tada Y, Takahashi H, Nagao T, Ojiri H, Masubuchi T, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol. 2018;29(4):979\u201384.","journal-title":"Ann Oncol"},{"issue":"2","key":"1275_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.18.00545","volume":"37","author":"H Takahashi","year":"2019","unstructured":"Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, et al. Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma. J Clin Oncol. 2019;37(2):125\u201334.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1275_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100602","volume":"7","author":"C van Herpen","year":"2022","unstructured":"van Herpen C, Vander Poorten V, Skalova A, Terhaard C, Maroldi R, van Engen A, et al. Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open. 2022;7(6): 100602.","journal-title":"ESMO Open"},{"key":"1275_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102069","volume":"89","author":"MJM Uijen","year":"2020","unstructured":"Uijen MJM, Lassche G, van Engen-van Grunsven ACH, Tada Y, Verhaegh GW, Schalken JA, et al. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review. Cancer Treat Rev. 2020;89: 102069.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"1275_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/cncr.33968","volume":"128","author":"LG Sousa","year":"2022","unstructured":"Sousa LG, Wang K, Torman D, Binks BJ, Rubin ML, Andersen CR, et al. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer. 2022;128(3):509\u201318.","journal-title":"Cancer"},{"issue":"10231","key":"1275_CR12","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316.","journal-title":"Lancet"},{"issue":"21","key":"1275_CR13","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1111\/bph.13576","volume":"173","author":"JC Evans","year":"2016","unstructured":"Evans JC, Malhotra M, Cryan JF, O\u2019Driscoll CM. The therapeutic and diagnostic potential of the prostate specific membrane antigen\/glutamate carboxypeptidase II (PSMA\/GCPII) in cancer and neurological disease. Br J Pharmacol. 2016;173(21):3041\u201379.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1275_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch\u00e4fers M, Essler M, et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 2017;58(1):85\u201390.","journal-title":"J Nucl Med"},{"issue":"6","key":"1275_CR15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825\u201333.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1275_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"10276","key":"1275_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804.","journal-title":"Lancet"},{"issue":"23","key":"1275_CR18","doi-asserted-by":"publisher","first-page":"9578","DOI":"10.1073\/pnas.1106383108","volume":"108","author":"MJ Evans","year":"2011","unstructured":"Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011;108(23):9578\u201382.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1275_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s13139-016-0439-4","volume":"51","author":"MK Bakht","year":"2017","unstructured":"Bakht MK, Oh SW, Youn H, Cheon GJ, Kwak C, Kang KW. Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges. Nucl Med Mol Imaging. 2017;51(3):202\u201311.","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"1275_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13550-018-0451-z","volume":"8","author":"K L\u00fcckerath","year":"2018","unstructured":"L\u00fcckerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, et al. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018;8(1):96.","journal-title":"EJNMMI Res"},{"issue":"1","key":"1275_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.116.181800","volume":"58","author":"TA Hope","year":"2017","unstructured":"Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, et al. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2017;58(1):81\u20134.","journal-title":"J Nucl Med"},{"issue":"1","key":"1275_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","volume":"1","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, et al. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018;1(1):78\u201382.","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"1275_CR23","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2967\/jnumed.118.223099","volume":"60","author":"L Emmett","year":"2019","unstructured":"Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, et al. Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial (68)Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade. J Nucl Med. 2019;60(7):950\u20134.","journal-title":"J Nucl Med"},{"issue":"3","key":"1275_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1590\/s1677-5538.ibju.2018.0305","volume":"45","author":"C Leitsmann","year":"2019","unstructured":"Leitsmann C, Thelen P, Schmid M, Meller J, Sahlmann CO, Meller B, et al. Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases? Int Braz J Urol. 2019;45(3):459\u201367.","journal-title":"Int Braz J Urol"},{"issue":"3","key":"1275_CR25","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00259-019-04635-7","volume":"47","author":"O Ettala","year":"2020","unstructured":"Ettala O, Malaspina S, Tuokkola T, Luoto P, L\u00f6yttyniemi E, Bostr\u00f6m PJ, et al. Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with (68)Ga-PSMA-11 PET\/MRI in men with treatment-na\u00efve prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47(3):665\u201373.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1275_CR26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00259-019-04674-0","volume":"47","author":"F Rosar","year":"2020","unstructured":"Rosar F, Dewes S, Ries M, Schaefer A, Khreish F, Maus S, et al. New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. Eur J Nucl Med Mol Imaging. 2020;47(3):687\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"1275_CR27","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.2967\/jnumed.120.259069","volume":"62","author":"KA Zukotynski","year":"2021","unstructured":"Zukotynski KA, Emmenegger U, Hotte S, Kapoor A, Fu W, Blackford AL, et al. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted (18)F-DCFPyL PET\/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. J Nucl Med. 2021;62(10):1430\u20137.","journal-title":"J Nucl Med"},{"issue":"2","key":"1275_CR28","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00259-022-05970-y","volume":"50","author":"S Malaspina","year":"2023","unstructured":"Malaspina S, Ettala O, Tolvanen T, Rajander J, Eskola O, Bostr\u00f6m PJ, et al. Flare on [(18)F]PSMA-1007 PET\/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-na\u00efve metastatic prostate cancer patients. Eur J Nucl Med Mol Imaging. 2023;50(2):613\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1275_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13550-023-01048-4","volume":"13","author":"I Sonni","year":"2023","unstructured":"Sonni I, Gafita A, Unterrainer LM, Alano RM, Lira S, Shen J, et al. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. EJNMMI Res. 2023;13(1):95.","journal-title":"EJNMMI Res"},{"issue":"5","key":"1275_CR30","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.7150\/thno.38501","volume":"10","author":"W van Boxtel","year":"2020","unstructured":"van Boxtel W, L\u00fctje S, van Engen-van Grunsven ICH, Verhaegh GW, Schalken JA, Jonker MA, et al. (68)Ga-PSMA-HBED-CC PET\/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics. 2020;10(5):2273\u201383.","journal-title":"Theranostics"},{"issue":"14","key":"1275_CR31","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.7150\/thno.99035","volume":"14","author":"NJ van Ruitenbeek","year":"2024","unstructured":"van Ruitenbeek NJ, Uijen MJM, Driessen CML, Peters SMB, Priv\u00e9 BM, van Engen-van Grunsven ACH, et al. Lutetium-177-PSMA therapy for recurrent\/metastatic salivary gland cancer: a prospective pilot study. Theranostics. 2024;14(14):5388\u201399.","journal-title":"Theranostics"},{"issue":"8","key":"1275_CR32","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/BF02985118","volume":"19","author":"H Otsuka","year":"2005","unstructured":"Otsuka H, Graham MM, Kogame M, Nishitani H. The impact of FDG-PET in the management of patients with salivary gland malignancy. Ann Nucl Med. 2005;19(8):691\u20134.","journal-title":"Ann Nucl Med"},{"issue":"8","key":"1275_CR33","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2967\/jnumed.107.041350","volume":"48","author":"HS Jeong","year":"2007","unstructured":"Jeong HS, Chung MK, Son YI, Choi JY, Kim HJ, Ko YH, et al. Role of 18F-FDG PET\/CT in management of high-grade salivary gland malignancies. J Nucl Med. 2007;48(8):1237\u201344.","journal-title":"J Nucl Med"},{"issue":"2","key":"1275_CR34","first-page":"240","volume":"48","author":"JL Roh","year":"2007","unstructured":"Roh JL, Ryu CH, Choi SH, Kim JS, Lee JH, Cho KJ, et al. Clinical utility of 18F-FDG PET for patients with salivary gland malignancies. J Nucl Med. 2007;48(2):240\u20136.","journal-title":"J Nucl Med"},{"key":"1275_CR35","doi-asserted-by":"crossref","unstructured":"Razfar A, Heron DE, Branstetter BFt, Seethala RR, Ferris RL. Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. Laryngoscope. 2010;120(4):734\u20138.","DOI":"10.1002\/lary.20829"},{"issue":"6","key":"1275_CR36","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2967\/jnumed.111.098384","volume":"53","author":"JY Kim","year":"2012","unstructured":"Kim JY, Lee SW, Kim JS, Kim SY, Nam SY, Choi SH, et al. Diagnostic value of neck node status using 18F-FDG PET for salivary duct carcinoma of the major salivary glands. J Nucl Med. 2012;53(6):881\u20136.","journal-title":"J Nucl Med"},{"issue":"3","key":"1275_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/MNM.0b013e32835bc4c4","volume":"34","author":"P Sharma","year":"2013","unstructured":"Sharma P, Jain TK, Singh H, Suman SK, Faizi NA, Kumar R, et al. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience. Nucl Med Commun. 2013;34(3):211\u20139.","journal-title":"Nucl Med Commun"},{"issue":"3","key":"1275_CR38","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1097\/RLU.0000000000001515","volume":"42","author":"MJ Park","year":"2017","unstructured":"Park MJ, Oh JS, Roh JL, Kim JS, Lee JH, Nam SY, et al. 18F-FDG PET\/CT Versus Contrast-Enhanced CT for Staging and Prognostic Prediction in Patients With Salivary Gland Carcinomas. Clin Nucl Med. 2017;42(3):e149\u201356.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"1275_CR39","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/odi.12877","volume":"24","author":"SH Lee","year":"2018","unstructured":"Lee SH, Roh JL, Kim JS, Lee JH, Choi SH, Nam SY, et al. Detection of distant metastasis and prognostic prediction of recurrent salivary gland carcinomas using (18) F-FDG PET\/CT. Oral Dis. 2018;24(6):940\u20137.","journal-title":"Oral Dis"},{"issue":"5","key":"1275_CR40","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.2214\/AJR.20.23259","volume":"216","author":"R Nakajima","year":"2021","unstructured":"Nakajima R, Patel SG, Katabi N, Flukes S, Mauguen A, Ganly I, et al. Diagnostic and Prognostic Utility of (18)F-FDG PET\/CT in Recurrent Salivary Gland Cancers. AJR Am J Roentgenol. 2021;216(5):1344\u201356.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"1275_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cpet.2021.12.002","volume":"17","author":"SM Broski","year":"2022","unstructured":"Broski SM, Johnson DR, Packard AT, Hunt CH. (18)F-fluorodeoxyglucose PET\/Computed Tomography: Head and Neck Salivary Gland Tumors. PET Clin. 2022;17(2):249\u201363.","journal-title":"PET Clin"},{"issue":"7","key":"1275_CR42","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/ph7070779","volume":"7","author":"M Eder","year":"2014","unstructured":"Eder M, Neels O, M\u00fcller M, Bauder-W\u00fcst U, Remde Y, Sch\u00e4fer M, et al. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals (Basel). 2014;7(7):779\u201396.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"1275_CR43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2967\/jnmt.114.152678","volume":"43","author":"W Jentzen","year":"2015","unstructured":"Jentzen W. An improved iterative thresholding method to delineate PET volumes using the delineation-averaged signal instead of the enclosed maximum signal. J Nucl Med Technol. 2015;43(1):28\u201335.","journal-title":"J Nucl Med Technol"},{"issue":"4","key":"1275_CR44","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","volume":"48","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48(4):1200\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1275_CR45","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","DOI":"10.1016\/j.ejca.2008.10.026"},{"issue":"6","key":"1275_CR46","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1210\/en.2007-1078","volume":"149","author":"A Godoy","year":"2008","unstructured":"Godoy A, Watts A, Sotomayor P, Montecinos VP, Huss WJ, Onate SA, et al. Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology. 2008;149(6):2959\u201369.","journal-title":"Endocrinology"},{"issue":"1","key":"1275_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2967\/jnumed.120.262250","volume":"63","author":"R Chen","year":"2022","unstructured":"Chen R, Wang Y, Zhu Y, Shi Y, Xu L, Huang G, et al. The Added Value of (18)F-FDG PET\/CT Compared with (68)Ga-PSMA PET\/CT in Patients with Castration-Resistant Prostate Cancer. J Nucl Med. 2022;63(1):69\u201375.","journal-title":"J Nucl Med"},{"issue":"6","key":"1275_CR48","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3892\/ijo.2012.1649","volume":"41","author":"T Liu","year":"2012","unstructured":"Liu T, Wu LY, Fulton MD, Johnson JM, Berkman CE. Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. Int J Oncol. 2012;41(6):2087\u201392.","journal-title":"Int J Oncol"},{"issue":"1","key":"1275_CR49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13550-020-00723-0","volume":"10","author":"S Hober\u00fcck","year":"2020","unstructured":"Hober\u00fcck S, L\u00f6ck S, Winzer R, Z\u00f6phel K, Froehner M, Fedders D, et al. [(68)Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. EJNMMI Res. 2020;10(1):135.","journal-title":"EJNMMI Res"},{"issue":"3","key":"1275_CR50","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00259-019-04581-4","volume":"47","author":"C Onal","year":"2020","unstructured":"Onal C, Guler OC, Torun N, Reyhan M, Yapar AF. The effect of androgen deprivation therapy on (68)Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47(3):632\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1275_CR51","doi-asserted-by":"crossref","unstructured":"Tseng JR, Chang SH, Wu YY, Fan KH, Yu KJ, Yang LY, et al. Impact of Three-Month Androgen Deprivation Therapy on [68Ga]Ga-PSMA-11 PET\/CT Indices in Men with Advanced Prostate Cancer-Results from a Pilot Prospective Study. Cancers (Basel). 2022;14(5).","DOI":"10.3390\/cancers14051329"},{"issue":"12","key":"1275_CR52","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00259-018-4079-z","volume":"45","author":"A Afshar-Oromieh","year":"2018","unstructured":"Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET\/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(12):2045\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01275-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01275-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01275-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T12:34:37Z","timestamp":1757248477000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-025-01275-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1275"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01275-x","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in adherence with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was approved by the Medical Review Ethics Committee Arnhem-Nijmegen, the Netherlands (NL71139.091.19). Written informed consent was obtained from all the participants before study enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"James Nagarajah has received research grants from ABX and Novartis, and has received consulting and teaching fees from ITM, POINT biopharma, CURIUM, Novartis, and Bayer. Carla van Herpen has been member of advisory boards for Bayer, Bristol-Myers Squibb, Elevar, Ipsen, MSD, and Regeneron, and has received research grants from Astra Zeneca, Bristol-Myers Squibb, MSD, Merck, Ipsen, Novartis, and Sanofi. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}